IKT Receives FDA Orphan Designation for Pulmonary Arterial Hypertension Treatment
Related Stocks: IKT
Read the full articleYou might also wanna read
TolerogenixX Has Received EMA Orphan Drug Designation for MIC-Lx, Strengthening its Regulatory Pathway in Kidney Transplantation
Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immuno
Insilico's AI-discovered lung fibrosis drug enters Phase III
Rentosertib will test whether Insilico's end-to-end AI drug discovery thesis can survive late-stage clinical scrutiny.
EQS-Adhoc: Pentixapharm Holding AG:Pentixapharm erhält FDA-Fast-Track-Status für [Ga]Ga-PentixaFor zur Subtypisierung des primären Aldosteronismus (deutsch)
Pentixapharm Holding AG:Pentixapharm erhält FDA-Fast-Track-Status für [Ga]Ga-PentixaFor zur Subtypisierung des primären Aldosteronismus ^ EQ
Cumberland Pharmaceuticals Inc. (CPIX) Stock: Unveils Special Dividend While Advancing Ifetroban Rare Disease Pipeline
TLDR CPIX declares a $1.50 special dividend after completing the Apotex transaction. Cumberland authorizes a $5M share buyback alongside its
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S.
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology compa
Comments
Sign in to join the conversation.
No comments yet. Be the first.